首頁 > 市場調查報告書 > 製藥

循環系統

市場調查報告書

商品編碼

1490919

血栓藥物市場- 按藥物類別（抗凝血劑[維生素K、DOA、肝素、Xa 抑制劑]、抗血小板藥物[P2Y12、阿斯匹靈、糖蛋白]、血栓溶解劑）、疾病類型（DVT、PE、VTE、 AT）、RoA、配銷通路- 全球預測，2024 - 2032

Thrombosis Drugs Market - By Drug Class (Anticoagulants [Vitamin K, DOA, Heparin, Xa Inhibitor], Antiplatelet Drugs [P2Y12, Aspirin, Glycoprotein], Thrombolytic), Disease Type (DVT, PE, VTE, AT), RoA, Distribution Channel - Global Forecast, 2024 - 2032

出版日期: 2024年03月22日 | 出版商:

Global Market Insights Inc. | 英文 150 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

由於深部靜脈血栓 (DVT) 和肺栓塞 (PE) 等血栓性疾病的盛行率不斷增加，預計血栓藥物市場規模在 2024 年至 2032 年間將呈現 8.2% 的複合年成長率。人口老化、久坐的生活方式以及肥胖和糖尿病等與生活方式相關的疾病發生率上升，都刺激了對血栓藥物的需求。

藥物傳輸技術、新型療法和口服抗凝血劑的引入的重大發展正在為增強治療選擇和改善患者預後鋪平道路。例如，2023年11月，美國FDA批准了Adzynma，這是第一個重組基因工程蛋白產品，設計用於診斷患有先天性血栓性血小板減少性紫斑症的成人和兒童患者進行預防性或按需酶替代治療。

此外，政府為提高對血栓形成的認知和改善醫療服務的可及性而採取的舉措正在積極影響市場的成長軌跡。

血栓藥物產業分為藥物類別、疾病類型、給藥途徑、配銷通路和地區。

就藥品類別而言，由於心血管疾病發生率上升，預計2024年至2032年抗血小板藥物領域的產業規模複合年成長率將達到8.5%。這些疾病需要抗血小板治療來預防心臟病和中風等血栓事件。藥物配方的不斷進步正在導致新型抗血小板藥物的開發，其功效和安全性得到改善。人們對預防保健和抗血栓治療重要性的認知不斷增強，將推動產品需求。

就疾病類型而言，到2032 年，深部靜脈栓塞(DVT) 領域的血栓藥物市場複合年成長率可能達到8.7%。率不斷增加。人口老化、久坐的生活方式和不斷上升的肥胖率正在推動 DVT 的流行，從而刺激了針對這種特定疾病類型的血栓形成藥物的需求。

從地區來看，由於心血管疾病以及肥胖和高血壓等相關危險因子的盛行率不斷上升，預計歐洲血栓藥物產業在 2024 年至 2032 年間將成長 7.6%。醫療保健支出的增加、藥物研究的進步以及強大的醫療保健基礎設施的存在正在增加這些藥物的消費。多項政府措施正在進一步促進預防性醫療保健措施並改善該地區獲得血栓治療的機會。

產業生態系統分析
產業影響力
- 成長動力
  - 血栓性疾病盛行率增加
  - 外科手術數量不斷增加
  - 藥物開發和技術的進步
  - 越來越重視預防保健
- 產業陷阱與挑戰
  - 與血栓藥物相關的高成本
  - 不良反應和副作用的風險
成長潛力分析
波特的分析
PESTEL分析
監管環境
技術景觀
報銷場景
2023 年定價分析
未來市場趨勢
缺口分析

第 4 章：競爭格局

介紹
公司矩陣分析
公司市佔率分析
競爭定位矩陣
戰略儀表板

第 5 章：市場估計與預測：按藥物類別，2021 - 2032 年

主要趨勢
抗凝血劑
- 直介面服抗凝血藥
- 肝素
- 維生素K拮抗劑
- Xa抑制劑
抗血小板藥物
- P2Y12血小板抑制劑
- 阿斯匹林
- 糖蛋白 IIb/IIIa 抑制劑
溶栓藥物

第 6 章：市場估計與預測：按疾病類型，2021 - 2032 年

主要趨勢
靜脈血栓栓塞
深層靜脈栓塞
肺栓塞
動脈血栓形成
其他疾病類型

第 7 章：市場估計與預測：按管理途徑，2021 - 2032 年

主要趨勢
口服
注射用
專題

第 8 章：市場估計與預測：按配銷通路分類，2021 - 2032 年

主要趨勢
醫院藥房
零售藥局
網路藥局

第 9 章：市場估計與預測：按地區，2021 - 2032

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 義大利
- 西班牙
- 歐洲其他地區
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地區
中東和非洲
- 沙烏地阿拉伯
- 南非
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 10 章：公司簡介

Amgen Inc.
Aspen Pharmacare Holdings Limited
Baxter International Inc.
Bayer AG
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Daiichi Sankyo Company, Limited
GlaxoSmithKline plc
Janssen Pharmaceuticals, Inc.
Novartis AG
Pfizer Inc.
Sanofi

簡介目錄

Product Code: 8685

Thrombosis Drugs Market size is projected to showcase 8.2% CAGR between 2024 and 2032, led by the increasing prevalence of thrombotic disorders, such as deep vein thrombosis (DVT) and pulmonary embolism (PE). The aging population, sedentary lifestyles, and rising incidence of lifestyle-related diseases like obesity and diabetes are fueling the demand for thrombosis drugs.

Significant developments in drug delivery technologies, novel therapeutics, and the introduction of oral anticoagulants are making way for enhanced treatment options and patient outcomes. For instance, in November 2023, the U.S. FDA authorized Adzynma, the first recombinant genetically engineered protein product designed for preventive or on-demand enzyme replacement therapy in adult and pediatric patients diagnosed with congenital thrombotic thrombocytopenic purpura.

Furthermore, government initiatives to raise awareness about thrombosis and improve access to healthcare services are positively influencing the market growth trajectory.

The thrombosis drugs industry is bifurcated into drug class, disease type, route of administration, distribution channel, and region.

In terms of drug class, the industry size from the antiplatelet drugs segment is expected to record 8.5% CAGR from 2024 to 2032, owing to the rising incidence of cardiovascular diseases. These ailments are necessitating antiplatelet therapies to prevent thrombotic events like heart attacks and strokes. Rising advancements in drug formulations is leading to the development of novel antiplatelet agents with improved efficacy and safety profiles. The growing awareness about preventive healthcare and the importance of antithrombotic therapy will drive the product demand.

With respect to disease type, the thrombosis drugs market from the deep vein thrombosis (DVT) segment may witness 8.7% CAGR through 2032. This can be attributed to the increasing incidence of DVT due to factors like prolonged immobility, surgery, and certain medical conditions. The aging population, sedentary lifestyles, and rising obesity rates are driving the prevalence of DVT, thereby fueling the demand for thrombosis drugs targeting this specific disease type.

Regionally, the Europe thrombosis drugs industry is projected to depict 7.6% gains between 2024 and 2032, due to growing prevalence of cardiovascular diseases and related risk factors like obesity and hypertension. The increasing healthcare expenditure, advancements in pharmaceutical research, and the presence of robust healthcare infrastructure are increasing the consumption of these drugs. Several government initiatives are further promoting preventive healthcare measures and improving access to thrombosis treatments in the region.

Chapter 1 Methodology & Scope

1.1 Market scope & definition
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of thrombotic disorders
  - 3.2.1.2 Rising number of surgical procedures
  - 3.2.1.3 Advancements in drug development and technology
  - 3.2.1.4 Growing emphasis on preventive healthcare
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 High cost associated with thrombosis drugs
  - 3.2.2.2 Risk of adverse reactions and side effects
3.3 Growth potential analysis
3.4 Porter's analysis
3.5 PESTEL analysis
3.6 Regulatory landscape
3.7 Technological landscape
3.8 Reimbursement scenario
3.9 Pricing analysis, 2023
3.10 Future market trends
3.11 Gap analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Anticoagulants
- 5.2.1 Direct oral anticoagulants
- 5.2.2 Heparin
- 5.2.3 Vitamin K antagonists
- 5.2.4 Xa Inhibitor
5.3 Antiplatelet drugs
- 5.3.1 P2Y12 platelet inhibitor
- 5.3.2 Aspirin
- 5.3.3 Glycoprotein IIb/IIIa inhibitors
5.4 Thrombolytic drugs

Chapter 6 Market Estimates and Forecast, By Disease Type, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Venous thromboembolism
6.3 Deep vein thrombosis
6.4 Pulmonary embolism
6.5 Arterial thrombosis
6.6 Other disease types

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Oral
7.3 Parenteral
7.4 Topical

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Hospital pharmacies
8.3 Retail pharmacies
8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Italy
- 9.3.5 Spain
- 9.3.6 Rest of Europe
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.5.4 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 Saudi Arabia
- 9.6.2 South Africa
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa